X4 Pharmaceuticals, Inc Quarterly Nonoperating Income (Expense) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
X4 Pharmaceuticals, Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2017 to Q3 2024.
  • X4 Pharmaceuticals, Inc Nonoperating Income (Expense) for the quarter ending September 30, 2024 was -$2.18M, a 109% decline year-over-year.
  • X4 Pharmaceuticals, Inc Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $9.21M.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2023 was $6.43M.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2022 was -$6.27M, a 75.5% decline from 2021.
  • X4 Pharmaceuticals, Inc annual Nonoperating Income (Expense) for 2021 was -$3.57M, a 69.4% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $9.21M -$2.18M -$27.1M -109% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 $36.3M $19.7M +$49.6M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$13.3M -$14.5M -$19.7M -373% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $6.43M $6.1M +$9.62M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$3.18M $24.9M +$26.4M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 -$29.6M -$29.9M -$29.3M -4585% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$308K $5.29M +$5.96M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 -$6.27M -$3.51M -$2.36M -206% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$3.91M -$1.45M -$391K -37.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$3.52M -$638K -$3K -0.47% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$3.51M -$674K +$60K +8.17% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$3.57M -$1.15M -$404K -54.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 -$3.17M -$1.05M -$585K -125% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$2.58M -$635K -$149K -30.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$2.43M -$734K -$325K -79.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$2.11M -$745K -$783K -2061% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 -$1.33M -$469K +$269K +36.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$1.6M -$486K -$517K -1668% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$1.08M -$409K +$26K +5.98% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$1.1M $38K +$3.27M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 -$4.37M -$738K -$681K -1195% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$3.69M $31K -$311K -90.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$3.38M -$435K +$822K +65.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$4.2M -$3.23M -$1.64M -104% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-19
Q3 2018 -$2.56M -$57K -$1.51M -104% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$1.04M $342K +$403K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$1.45M -$1.26M -$1.7M -384% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $253K -$1.58M Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $1.46M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$61K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $442K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.